Cerebral amyloid and hypertension are independently associated with white matter lesions in elderly

Frontiers in Aging Neuroscience

Volumn 7, Issue DEC, 2015, Pages

  Scott, Julia A ^a   Braskie, Meredith N ^b   Tosun, Duygu ^c   Thompson, Paul M ^b   Weiner, Michael ^c   DeCarli, Charles ^a   Carmichael, Owen T ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

ADNI; Amyloid; FLAIR; Hypertension; MRI; Normal aging

Indexed keywords

AMYLOID BETA PROTEIN[1-42];

AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CEREBROSPINAL FLUID LEVEL; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERTENSION; LATENT PERIOD; MAJOR CLINICAL STUDY; MALE; NERVOUS SYSTEM PARAMETERS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; RISK ASSESSMENT; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; WHITE MATTER HYPERINTENSITY VOLUME; WHITE MATTER LESION;

EID: 84953874365     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2015.00221     Document Type: Article

References (45)

1. Allan, C. L., Zsoldos, E., Filippini, N., Sexton, C. E., Topiwala, A., Valkanova, V., et al. (2014). Lifetime hypertension as a predictor of brain structure in older adults: cohort study with a 28-year follow up. Br. J. Psychiatry 206, 308-315. doi: 10.1192/bjp.bp.114.153536
2. Barnes, J., Carmichael, O. T., Leung, K. K., Schwarz, C., Ridgway, G. R., Bartlett, J. W., et al. (2013). Vascular and Alzheimer's disease markers independently predict brain atrophy rate in Alzheimer's Disease Neuroimaging Initiative controls. Neurobiol. Aging 34, 1996-2002. doi: 10.1016/j.neurobiolaging.2013.02.003
3. Baumgart, M., Snyder, H. M., Carrillo, M. C., Fazio, S., Kim, H., and Johns, H. (2015). Summary of the evidence on modifiable risk factors for cognitive decline and dementia: a population-based perspective. Alzheimers Dement 11, 718-726. doi: 10.1016/j.jalz.2015.05.016
4. Belsley, D. A., Kuh, E., and Welsch, R. E. (1980). Regression Diagnostics: Identifying Influential Data and Sources of Collinearity. New York, NY: John Wiley and Sons.
5. Black, S., Gao, F., and Bilbao, J. (2009). Understanding white matter disease: imaging-pathological correlations in vascular cognitive impairment. Stroke 40, S48-S52. doi: 10.1161/STROKEAHA.108.537704
6. Bots, M. L., Breteler, M. M. B., Hofman, A., Grobbee, D. E., van Swieten, J. C., van Gijn, J., et al. (1993). Cerebral white matter lesions and atherosclerosis in the Rotterdam Study. Lancet 341, 1232-1237. doi: 10.1016/0140-6736(93)91144-B
7. Brickman, A. M. (2013). Contemplating Alzheimer's disease and the contribution of white matter hyperintensities. Curr. Neurol. Neurosci. Rep. 13:415. doi: 10.1007/s11910-013-0415-7
8. Brickman, A. M., Guzman, V. A., Gonzalez-Castellon, M., Razlighi, Q., Gu, Y., Narkhede, A., et al. (2015). Cerebral autoregulation, beta amyloid, and white matter hyperintensities are interrelated. Neurosci. Lett. 592, 54-58. doi: 10.1016/j.neulet.2015.03.005
9. Carmichael, O., Schwarz, C., Drucker, D., Fletcher, E., Harvey, D., Beckett, L., et al. (2010). Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Arch. Neurol. 67, 1370-1378. doi: 10.1001/archneurol.2010.284
10. Cognat, E., Cleophax, S., Domenga-Denier, V., and Joutel, A. (2014). Early white matter changes in CADASIL: evidence of segmental intramyelinic oedema in a pre-clinical mouse model. Acta Neuropathol. Commun. 2:49. doi: 10.1186/2051-5960-2-49
11. D'Agostino, R. B. Sr., Vasan, R. S., Pencina, M. J., Wolf, P. A., Cobain, M., Massaro, J. M., et al. (2008). General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117, 743-753. doi: 10.1161/CIRCULATIONAHA.107.699579
12. Debette, S., Seshadri, S., Beiser, A., Au, R., Himali, J. J., Palumbo, C., et al. (2011). Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology 77, 461-468. doi: 10.1212/WNL.0b013e318227b227
13. de Bruijn, R. F., Akoudad, S., Cremers, L. G., Hofman, A., Niessen, W. J., van der Lugt, A., et al. (2014). Determinants. MRI correlates, and prognosis of mild cognitive impairment: the Rotterdam Study. J. Alzheimers. Dis. 42(Suppl. 3), S239-S249. doi: 10.3233/JAD-132558
14. de Leeuw, F. E., de Groot, J. C., Oudkerk, M., Witteman, J. C., Hofman, A., van Gijn, J., et al. (1999). A follow-up study of blood pressure and cerebral white matter lesions. Ann. Neurol. 46, 827-833. doi: 10.1002/1531-8249(199912)46:6 < 827::AID-ANA4 > 3.0.CO;2-H
15. Dufouil, C., Chalmers, J., Coskun, O., Besancon, V., Bousser, M. G., Guillon, P., et al. (2005). Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation 112, 1644-1650. doi: 10.1161/CIRCULATIONAHA.104.501163
16. Geijselaers, S. L., Sep, S. J., Stehouwer, C. D., and Biessels, G. J. (2015). Glucose regulation, cognition, and brain MRI in type 2 diabetes: a systematic review. Lancet Diabetes Endocrinol. 3, 75-89. doi: 10.1016/S2213-8587(14)70148-2
17. Godin, O., Tzourio, C., Maillard, P., Mazoyer, B., and Dufouil, C. (2011). Antihypertensive treatment and change in blood pressure are associated with the progression of white matter lesion volumesclinical perspective the three-city (3C)-Dijon magnetic resonance imaging study. Circulation 123, 266-273. doi: 10.1161/CIRCULATIONAHA.110.961052
18. Gouw, A. A., Seewann, A., van der Flier, W. M., Barkhof, F., Rozemuller, A. M., Scheltens, P., et al. (2011). Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J. Neurol. Neurosurg. Psychiatry 82, 126-135. doi: 10.1136/jnnp.2009.204685
19. Guzman, V. A., Carmichael, O. T., Schwarz, C., Tosto, G., Zimmerman, M. E., Brickman, A. M., et al. (2013). White matter hyperintensities and amyloid are independently associated with entorhinal cortex volume among individuals with mild cognitive impairment. Alzheimers Dement 9, S124-S131. doi: 10.1016/j.jalz.2012.11.009
20. Haight, T. J., Landau, S. M., Carmichael, O., Schwarz, C., DeCarli, C., Jagust, W. J., et al. (2013). Dissociable effects of Alzheimer disease and white matter hyperintensities on brain metabolism. JAMA Neurol. 70, 1039-1045. doi: 10.1001/jamaneurol.2013.1878
21. Hughes, T. M., Kuller, L. H., Lopez, O. L., Becker, J. T., Evans, R. W., Sutton-Tyrrell, K., et al. (2012). Markers of cholesterol metabolism in the brain show stronger associations with cerebrovascular disease than Alzheimer's disease. J. Alzheimers. Dis. 30, 53-61. doi: 10.3233/JAD-2012-111460
22. Kaffashian, S., Tzourio, C., Soumare, A., Dufouil, C., Zhu, Y., Crivello, F., et al. (2014). Plasma beta-amyloid and MRI markers of cerebral small vessel disease: three-City Dijon study. Neurology 83, 2038-2045. doi: 10.1212/WNL.0000000000001038
23. Landau, S. M., Breault, C., Joshi, A. D., Pontecorvo, M., Mathis, C. A., Jagust, W. J., et al. (2013). Amyloid-beta imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J. Nucl. Med. 54, 70-77. doi: 10.2967/jnumed.112.109009
24. Launer, L. J., Hughes, T., Yu, B., Masaki, K., Petrovitch, H., Ross, G. W., et al. (2010). Lowering midlife levels of systolic blood pressure as a public health strategy to reduce late-life dementia: perspective from the Honolulu Heart Program/Honolulu Asia Aging Study. Hypertension 55, 1352-1359. doi: 10.1161/HYPERTENSIONAHA.109.147389
25. Lo, R. Y., Jagust, W. J., and Alzheimer's Disease Neuroimaging, I. (2012). Vascular burden and Alzheimer disease pathologic progression. Neurology 79, 1349-1355. doi: 10.1212/WNL.0b013e31826c1b9d
26. Nettiksimmons, J., Beckett, L., Schwarz, C., Carmichael, O., Fletcher, E., and Decarli, C. (2013). Subgroup of ADNI normal controls characterized by atrophy and cognitive decline associated with vascular damage. Psychol. Aging 28, 191-201. doi: 10.1037/a0031063
27. Pike, K. E., Savage, G., Villemagne, V. L., Ng, S., Moss, S. A., Maruff, P., et al. (2007). Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 130, 2837-2844. doi: 10.1093/brain/awm238
28. Preston, S. D., Steart, P. V., Wilkinson, A., Nicoll, J. A., and Weller, R. O. (2003). Capillary and arterial cerebral amyloid angiopathy in Alzheimer's disease: defining the perivascular route for the elimination of amyloid beta from the human brain. Neuropathol. Appl. Neurobiol. 29, 106-117. doi: 10.1046/j.1365-2990.2003.00424.x
29. Price, J. L., and Morris, J. C. (1999). Tangles and plaques in nondemented aging and "preclinical". Alzheimer's disease. Ann. Neurol. 45, 358-368.
30. Provenzano, F. A., Muraskin, J., Tosto, G., Narkhede, A., Wasserman, B. T., Griffith, E. Y., et al. (2013). White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease? JAMA Neurol. 70, 455-461. doi: 10.1001/jamaneurol.2013.1321
31. Romero, J. R., Beiser, A., Seshadri, S., Benjamin, E. J., Polak, J. F., Vasan, R. S., et al. (2009). Carotid artery atherosclerosis. MRI indices of brain ischemia, aging, and cognitive impairment: the Framingham study. Stroke 40, 1590-1596. doi: 10.1161/STROKEAHA.108.535245
32. Rosano, C., Abebe, K. Z., Aizenstein, H. J., Boudreau, R., Jennings, J. R., Venkatraman, V., et al. (2014). Longitudinal systolic blood pressure characteristics and integrity of white matter tracts in a cohort of very old black and white adults. Am. J. Hypertens 28, 326-334. doi: 10.1093/ajh/hpu134
33. Schmidt, R., Hayn, M., Fazekas, F., Kapeller, P., and Esterbauer, H. (1996). Magnetic resonance imaging white matter hyperintensities in clinically normal elderly individuals. Correlations with plasma concentrations of naturally occurring antioxidants. Stroke 27, 2043-2047.
34. Shaw, L. M., Vanderstichele, H., Knapik-Czajka, M., Figurski, M., Coart, E., Blennow, K., et al. (2011). Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol. 121, 597-609. doi: 10.1007/s00401-011-0808-0
35. Snyder, H. M., Corriveau, R. A., Craft, S., Faber, J. E., Greenberg, S. M., Knopman, D., et al. (2015). Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. Alzheimers Dement 11, 710-717. doi: 10.1016/j.jalz.2014.10.008
36. Stenset, V., Johnsen, L., Kocot, D., Negaard, A., Skinningsrud, A., Gulbrandsen, P., et al. (2006). Associations between white matter lesions, cerebrovascular risk factors, and low CSF Abeta42. Neurology 67, 830-833. doi: 10.1212/01.wnl.0000234030.77831.5a
37. Swan, G. E., DeCarli, C., Miller, B. L., Reed, T., Wolf, P. A., Jack, L. M., et al. (1998). Association of midlife blood pressure to late-life cognitive decline and brain morphology. Neurology 51, 986-993. doi: 10.1212/WNL.51.4.986
38. Thomas, T., Thomas, G., McLendon, C., Sutton, T., and Mullan, M. (1996). beta-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380, 168-171. doi: 10.1038/380168a0
39. van der Kooij, A. J. (2007). Prediction Accuracy and Stability of Regression with Optimal Scaling Transformations, Ph.D. thesis, Leiden University, Leiden.
40. van Norden, A. G., van Dijk, E. J., de Laat, K. F., Scheltens, P., Olderikkert, M. G., and de Leeuw, F. E. (2012). Dementia: Alzheimer pathology and vascular factors: from mutually exclusive to interaction. Biochim. Biophys. Acta 1822, 340-349. doi: 10.1016/j.bbadis.2011.07.003
41. Verhaaren, B. F., Vernooij, M. W., de Boer, R., Hofman, A., Niessen, W. J., van der Lugt, A., et al. (2013). High blood pressure and cerebral white matter lesion progression in the general population. Hypertension 61, 1354-1359. doi: 10.1161/HYPERTENSIONAHA.111.00430
42. Wardlaw, J. M., Smith, E. E., Biessels, G. J., Cordonnier, C., Fazekas, F., Frayne, R., et al. (2013). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 12, 822-838. doi: 10.1016/S1474-4422(13)70124-8
43. Willey, J. Z., Gardener, H., Moon, Y. P., Yoshita, M., DeCarli, C., Cheung, Y. K., et al. (2014). Lipid profile components and subclinical cerebrovascular disease in the northern Manhattan study. Cerebrovasc. Dis. 37, 423-430. doi: 10.1159/000362920
44. Yamada, M., and Naiki, H. (2012). Cerebral amyloid angiopathy. Prog. Mol. Biol. Transl. Sci. 107, 41-78. doi: 10.1016/B978-0-12-385883-2.00006-0
45. Yoshita, M., Fletcher, E., Harvey, D., Ortega, M., Martinez, O., Mungas, D. M., et al. (2006). Extent and distribution of white matter hyperintensities in normal aging. MCI, and AD. Neurology 67, 2192-2198. doi: 10.1212/01.wnl.0000249119.95747.1f